Loading…
Loading…
EVOK (Evoke Pharma, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
EVOK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EVOK and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EVOK and 80,000+ other tickers.
See exactly how EVOK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EVOK and 80,000+ other tickers.
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive…
Evoke LON: EVOK reported stable first-half revenue and lower adjusted EBITDA as increased gaming duties, particularly in the U.K., added a £46 million year-on-year cost headwind. Management said mitigation efforts, including more efficient marketing, cost savings and retail estate changes, offset more than half of the impact during the period.
Evoke PLC (LSE:EVOK), the gambling group that owns William Hill, 888 and Mr Green, has agreed to a £243 million all-share takeover by Bally's Intralot, the Athens-listed lottery and gaming operator, sending its shares 16% higher to 46.45p. The recommended offer values Evoke at 52p per share and includes a partial cash alternative.
Evoke shareholders will be entitled to receive 0.537 new Intralot shares for each Evoke share. The deal is expected completed the deal by the first quarter of 2027.
William Hill UK owner Evoke said on Friday it had agreed to be acquired by Bally's Intralot S.A. in a recommended all-share deal valuing the company at about £243 million ($326.23 million).
William Hill owner Evoke PLC (LSE:EVOK) has confirmed it is in talks about being taken over by Greek-US lottery and gambling outfit Bally's Intralot. The bookmaker said a proposed offer valuing the group at 50p per share is being discussed, via an all-share combination, alongside a partial cash alternative.